Upload File

26511996_ tocilizumab in early progressive rheumatoid arthritis_ function, a randomised controlled...

  • Home
  • Documents
  • 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial
prev
next
out of 13
Download 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

Upload: laila-mayangsari

Post on 27-Feb-2018

219 views

Category:

Documents


0 download

Report

TRANSCRIPT

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    1/13

    http://group.bmj.com/http://ard.bmj.com/http://www.eular.org/http://ard.bmj.com/http://dx.doi.org/10.1136/annrheumdis-2015-207628http://dx.doi.org/10.1136/annrheumdis-2015-207628http://dx.doi.org/10.1136/annrheumdis-2015-207628

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    2/13

    http://group.bmj.com/http://ard.bmj.com/http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    3/13

    http://group.bmj.com/http://ard.bmj.com/http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    4/13

    http://group.bmj.com/http://ard.bmj.com/

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    5/13

    http://group.bmj.com/http://ard.bmj.com/

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    6/13

    http://group.bmj.com/http://ard.bmj.com/

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    7/13

    http://group.bmj.com/http://ard.bmj.com/

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    8/13

    http://group.bmj.com/http://ard.bmj.com/http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2015-207628/-/DC1

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    9/13

    http://group.bmj.com/http://ard.bmj.com/

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    10/13

    http://group.bmj.com/http://ard.bmj.com/http://dx.doi.org/10.1002/art.1780310614http://dx.doi.org/10.1093/rheumatology/kep329http://dx.doi.org/10.1136/annrheumdis-2013-204573http://dx.doi.org/10.1002/acr.21641http://dx.doi.org/10.1002/acr.21641http://dx.doi.org/10.1002/art.20568http://dx.doi.org/10.1002/art.27268http://dx.doi.org/10.1002/art.27268http://creativecommons.org/licenses/by-nc/4.0/http://creativecommons.org/licenses/by-nc/4.0/

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    11/13

    http://group.bmj.com/http://ard.bmj.com/http://dx.doi.org/10.1002/art.37711http://dx.doi.org/10.1002/art.24638http://dx.doi.org/10.1136/ard.2010.137703http://dx.doi.org/10.1136/ard.2008.101121http://dx.doi.org/10.1002/art.21519http://dx.doi.org/10.1002/1529-0131(199809)41:9%3C1571::AID-ART7%3E3.0.CO;2-Rhttp://dx.doi.org/10.1136/ard.62.7.611http://dx.doi.org/10.1586/ecp.11.33http://dx.doi.org/10.1136/annrheumdis-2013-204769http://dx.doi.org/10.1136/ard.2010.138461http://dx.doi.org/10.1136/annrheumdis-2011-201282http://dx.doi.org/10.1016/S0140-6736(13)60250-0http://dx.doi.org/10.1002/art.30158http://dx.doi.org/10.1002/art.30158http://dx.doi.org/10.1002/art.23940http://dx.doi.org/10.1016/S0140-6736(08)60453-5http://dx.doi.org/10.1136/ard.2008.105197http://dx.doi.org/10.1136/ard.2008.092932http://dx.doi.org/10.1182/blood-2008-05-155846http://dx.doi.org/10.1136/annrheumdis-2011-200975

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    12/13

    http://group.bmj.com/http://ard.bmj.com/http://group.bmj.com/subscribe/http://journals.bmj.com/cgi/reprintformhttp://group.bmj.com/group/rights-licensing/permissionshttp://ard.bmj.com//cgi/collection/rheumatoid_arthritishttp://ard.bmj.com//cgi/collection/musculoskeletal_syndromeshttp://ard.bmj.com//cgi/collection/immunology_including_allergyhttp://ard.bmj.com//cgi/collection/epidemiologyhttp://ard.bmj.com//cgi/collection/degenerative_joint_diseasehttp://ard.bmj.com//cgi/collection/connective_tissue_diseasehttp://ard.bmj.com//cgi/collection/unlockedhttp://creativecommons.org/licenses/by-nc/4.0/http://ard.bmj.com/content/early/2015/10/28/annrheumdis-2015-207628#BIBLhttp://ard.bmj.com/content/early/2015/10/28/annrheumdis-2015-207628#BIBLhttp://ard.bmj.com/content/suppl/2015/10/28/annrheumdis-2015-207628.DC1.htmlhttp://ard.bmj.com/content/suppl/2015/10/28/annrheumdis-2015-207628.DC1.htmlhttp://ard.bmj.com/content/early/2015/10/28/annrheumdis-2015-207628http://ard.bmj.com/content/early/2015/10/28/annrheumdis-2015-207628

  • 7/25/2019 26511996_ Tocilizumab in Early Progressive Rheumatoid Arthritis_ FUNCTION, A Randomised Controlled Trial

    13/13

    http://group.bmj.com/http://ard.bmj.com/http://group.bmj.com/subscribe/http://journals.bmj.com/cgi/reprintformhttp://group.bmj.com/group/rights-licensing/permissions

Skeletal System Diseases and Disorders. Arthritis Rheumatoid Rheumatoid Osteoarthritis Osteoarthritis Juvenile Rheumatoid Arthritis Juvenile Rheumatoid

BMJ...2016/11/02  · Confidential: For Review Only Ultrasound in the management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial Journal: BMJ Manuscript ID BMJ.2016.031902

Actemra® (Tocilizumab) Injection for Intravenous InfusionActemra is dosed according to U.S. Food and Drug Administration labeled dosing for rheumatoid arthritis up to a maximum of

Tocilizumab for the treatment of rheumatoid arthritis · 2020. 7. 17. · Javier Rueda-Gotor*, Miguel A González-Gay & Ricardo Blanco Summary Tocilizumab (TCZ) is a humanized monoclonal

L'étude TOWARD : Tocilizumab in cOmbination With traditional DMARD therapy (tocilizumab en association avec un traitement traditionnel par DMARD)

AusPAR Attachment: Product Information Tocilizumab (rch) · Web viewAUSTRALIAN PRODUCT INFORMATION Actemra ® (tocilizumab) Attachment 1: Product information for AusPAR – ACTEMRA

Review Mortality in tocilizumab-treated patients with

The Role of Tocilizumab in the Treatment of Rheumatoid ...cdn.intechopen.com/.../InTech...the_treatment_of_rheumatoid_arthritis.pdf · The Role of Tocilizumab in the Treatment of

Tocilizumab: A Review in Rheumatoid Arthritis · idiopathic arthritis, juvenileidiopathic polyarthritis and giant cell arteritis in adults [2, 3], with discussion of these indica-tions

Neutropenia During Tocilizumab Treatment Is Not Associated

TOCILIZUMAB IN GIANT CELL ARTERITIS. OBSERVATIONAL, …

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid … · 2017. 7. 3. · bilirubin are associated with clinical evidence of hepatic decompensation.1,6,7 Indeed, other etiologies

AusPAR Attachment 1: Tocilizumab (rch)

Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis New Evidence reports on presentations given

BMJ€¦ · OBJECTIVE: Three non-tumor-necrosis factor-alpha (TNF) inhibitors — rituximab, abatacept and tocilizumab — are widely used in patients with rheumatoid arthritis (RA)

Clinical Commissioning Policy: Tocilizumab for Takayasu arteritis

Tocilizumab for COVID -19

Prior Authorization Protocol ACTEMRA (tocilizumab), CIMZIA … · 2017-02-02 · Prior Authorization Protocol ACTEMRA ® (tocilizumab), CIMZIA ® (certolizumab pegol), COSENTYX ®

Sustainability of TNF-blocker tapering in rheumatoid ... · Rheumatoid arthritis Figure 1 Flow chart of the STRASS RCT and the 3-year extension study. RCT, randomised controlled trial;

Het medicijn Tocilizumab - Hetwkz-kind.nl

Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid

Arthritis Advisory Committee July 29, 2008 Actemra (tocilizumab) for Rheumatoid Arthritis FDA Perspective Sarah Okada, M.D. Division of Anesthesia, Analgesia,

eprints.soton.ac.uk20print... · Web viewExercises to improve function of the rheumatoid hand: a randomised controlled trial. Sarah E Lamb . DPhil . 1,2*, Esther M Williamson . PhD

Active immunization with Tocilizumab mimotopes induces

EXTENDED REPORT Assessment of short-term symptomatic ... · EXTENDED REPORT Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised,

Section/item ItemNo Description Administrative information10.1186... · Administrative information Title 1 Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis

Tocilizumab Streamlined IPU application for applicant

THE USE OF TOCILIZUMAB (ACTEMRA ® ), AN INTERLEUKIN-6 RECEPTOR ANTAGONIST, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN METHOTREXATE REFRACTORY PATIENTS

Tocilizumab might prevent cardiovascular disease in rheumatoid … · 2017. 3. 6. · 1 Tocilizumab might prevent cardiovascular disease in rheumatoid arthritis patients through the

A tocilizumab (RoActemra szerepe a rheumatoid …unipub.lib.uni-corvinus.hu/438/1/tocilizumab.pdf4 Szakmai lektorok Prof. Czirják László dr. , igazgató, Pécsi Tudományegyetem

Tocilizumab Resistant Nephrotic Syndrome and Protein Losing Gastroeneropathy … · Tocilizumab Resistant Nephrotic Syndrome 4 hypertrophy, suggesting cardiac amyloidosis. Due to

Personal weight scale RADAR Rheumatoid Arthritis Exclusion ... (2)_PROT… · RADAR Rheumatoid Arthritis Exclusion Diet An Online Randomised Controlled Trial Amanda Burls1, Amy Price2,

Tocilizumab for the treatment of rheumatoid arthritis ... 10 Mus… · 1.2 People currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet the criteria

ACTEMRA® (tocilizumab) aspectos destacados sobre la

Tocilizumab-induced Transaminitis in a Seropositive